Rapid and sustained response to a single dose of sertraline in a patient with newly emergent depression during varenicline-assisted smoking cessation

CNS Spectrums

Volumn 15, Issue 3, 2010, Pages 148-151

  Baran, Xiaolei Yu ^a,b   Docherty, John P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE; VARENICLINE; ANTIDEPRESSANT AGENT; BENZAZEPINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ADULT; ANHEDONIA; CASE REPORT; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; DRUG RESPONSE; HOPELESSNESS; HUMAN; LETTER; MALE; MOOD CHANGE; MORNING DOSAGE; NIGHTMARE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SLEEP DISORDER; SMOKING CESSATION; THOUGHT DISORDER; TOBACCO DEPENDENCE; VIVID DREAM; WEIGHT GAIN; PSYCHOLOGICAL ASPECT;

ADULT; ANTIDEPRESSIVE AGENTS; BENZAZEPINES; DEPRESSIVE DISORDER; HUMANS; MALE; QUINOXALINES; SERTRALINE; SMOKING CESSATION;

EID: 77952299555     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900027401     Document Type: Letter

References (27)

1. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry. 1997;154:263-265.
2. Tsoh JY, Humfleet GL, Muñoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157:368-374.
3. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA. 1990;264:1546-1549.
4. Hall SM, Muñoz RF, Reus VI, Sees KL. Nicotine, negative affect, and depression. J Consult Clin Psychol. 1993;61:761-767.
5. Rollema H, Hajós M, Seymour PA, et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol. 2009;78:813-824.
6. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf. 2009;32:499-507.
7. Imperato AA, Mulas A, Di Chiara G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol. 1986;132:337-338.
8. Grosshans M, Mutschler J, Hermann D, Mann K, Diehl A. Reduced affective symptoms during tobacco dependence treatment with varenicline. Addiction. 2009;104:859-861.
9. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:1026-1031.
10. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008;165:774.
11. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm. 2008;65:1624-1626.
12. FDA Drug Safety Newsletter. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm169988.htm. Accessed: February 11, 2010.
13. Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol. 2008;28:720-721.
14. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13:511-514.
15. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:1269-1270.
16. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
17. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006;60:571-576.
18. Andreasen JT, Olsen GM, Wiborg O, Redrobe JP. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol. 2009;23:797-804.
19. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007;28:316-235.
20. Rollema H, Guanowsky V, Mineur YS, et al. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol. 2009;605:114-116.
21. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65:144-149.
22. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:1026-1031.
23. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
24. Daamen MJ, Brown WA. Single-dose fluoxetine in management of premenstrual syndrome. J Clin Psychiatry. 1992;53:210-211.
25. Ahrens T, Frankhauser P, Lederbogen F, Deuschle M. Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function. J Clin Psychopharmacol. 2007;27:602-606.
26. Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol. 2009;32:117-118.
27. Liu ME, Tsai SJ, Yang ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizoaffective disorder. CNS Spectr. 2009;14:346.